Jean-Marie Michot, MD, is a medical doctor in the Department of Hematology and Innovative Drugs at the Institut de Cancérologie Gustave Roussy.

Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL

“[This is the] first study to evaluate the replacement of rituximab with odronextamab, which is a [CD20/CD3-targeted] bispecific antibody, in combination with CHOP for patients with previously untreated DLBCL.”

Jean-Marie Michot, MD, a medical doctor in the Department of Hematology and Innovative Drugs at the Institut de Cancérologie Gustave Roussy, discussed the potential clinical relevance of the findings from part 1A of the phase 3 OLYMPIA-3 study (NCT06091865) investigating odronextamab (Ordspono) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Videos

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

Jean-Marie Michot, MD, medical oncologist, the Department of Hematology and Innovative Drugs, the Institut de Cancérologie Gustave Roussy, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma (NHL).

Because there are few options for treatment in patients with relapsed/refractory NHL, investigations are ongoing to find new chemotherapy-free therapy options, Michot says. This has led to the examination of CC-99282 as a chemotherapy-free treatment, and the agent is based on protein degraders acting as molecular glue degraders, Michot explains.

Preclinical models demonstrated that when compared with other immunomodulatory agents, CC-99282 produced an increased apoptotic and antiproliferative activity, Michot adds. These data led to the rationale of utilizing this agent in a phase 1 trial (NCT03930953), where findings from the dose escalation portion of the trial showed that CC-99282 demonstrated encouraging responses and a favorable safety profile, with low rates of serious febrile neutropenia, Michot concludes.

Jean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.

Jean-Marie Michot, MD

Articles

Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL

Dr. Michot on the Examination of CC-99282 in Relapsed/Refractory NHL